ACTR3B

Across TCGA pan-cancer cohorts, ACTR3B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTR3B data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ACTR3B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTR3B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, ESCA, and LUAD are the cancer types where ACTR3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.056	0.556	<.001	9	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LUAD	DFS	Median	II,III,IV	0.098	0.682	<.001	6	view →
UCEC	DFS	Median	All	0.951	0.633	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTR3B–LIHC (DFS)

Open the LIHC breakdown →